RESEARCH ARTICLE

Evaluation of the Abbott ARCHITECT HIV Ag/Ab combo assay for determining recent HIV-1 infection

Kelly A. Curtis1*, Donna L. Rudolph1, Yi Pan1, Kevin Delaney1, Kathryn Anastas2, Jack DeHovitz3, Seble G. Kassaye4, Carl V. Hanson5, Audrey L. French6, Elizabeth Golub7, Adaora A. Adimora8, Igho Ofotokun9, Hector Bolivar10, Mirjam-Colette Kempf11, Philip J. Peters1, William M. Switzer1

1 Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, 2 Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, United States of America, 3 Downstate Medical Center, State University of New York, Brooklyn, New York, United States of America, 4 Department of Medicine / Division of Infectious Diseases, Georgetown University, Washington, DC, United States of America, 5 California State Department of Health, Berkeley, California, United States of America, 6 Department of Medicine, Stroger Hospital of Cook County, Chicago, Illinois, United States of America, 7 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America, 8 Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, 9 Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, United States of America, 10 Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, United States of America, 11 School of Nursing, Public Health and Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America

* cvz2@cdc.gov

Abstract

Background

Given the challenges and costs associated with implementing HIV-1 incidence assay testing, there is great interest in evaluating the use of commercial HIV diagnostic tests for determining recent HIV infection. A diagnostic test with the capability of providing reliable data for the determination of recent HIV infection without substantial modifications to the test protocol would have a significant impact on HIV surveillance. The Abbott ARCHITECT HIV Ag/Ab Combo Assay is an antigen/antibody immunoassay, which meets the criteria as the first screening test in the recommended HIV laboratory diagnostic algorithm for the United States.

Methods

In this study, we evaluated the performance characteristics of the ARCHITECT HIV Ag/Ab Combo signal-to-cutoff ratio (S/Co) for determining recent infection, including estimation of the mean duration of recent infection (MDRI) and false recent rate (FRR), and selection of recency cutoffs.

Results

The MDRI estimates for the S/Co recency cutoff of 400 is within the 4 to 12 months range recommended for HIV incidence assays, and the FRR rate for this cutoff was 1.5%.
Additionally, ARCHITECT Combo S/Co values were compared relative to diagnostic test results from two prior prospective HIV-1 diagnostic studies in order to validate the use of the S/Co for both diagnostic and recency determination.

**Conclusion**

Dual-use of the ARCHITECT Combo assay data for diagnostic and incidence purposes would reduce the need for separate HIV incidence testing and allow for monitoring of recent infection for incidence estimation and other public health applications.

**Introduction**

In 2014, Centers for Disease Control and Prevention (CDC) and the Association of Public Health Laboratories (APHL) issued updated HIV testing recommendations for laboratory diagnosis of HIV in the United States (US) [1]. The revised guidelines recommend use of Food and Drug Administration (FDA)-approved HIV tests with improved detection of acute HIV-1 infection, as well as HIV-2. The recommended diagnostic algorithm involves screening with a HIV-1/HIV-2 antigen (Ag)/antibody (Ab) combination immunoassay, followed by confirmation with an HIV-1/HIV-2 antibody differentiation immunoassay. Specimens that yield discordant or indeterminate immunoassay test results should be resolved with an HIV-1 nucleic acid test (NAT) to diagnose potential acute infection. Several studies have addressed the performance of the diagnostic algorithm with various combinations of FDA-approved diagnostic tests that meet the algorithm criteria [2–6]. The ARCHITECT HIV Ag/Ab Combo assay ([ARCHITECT] Abbott Laboratories, Chicago, IL) is one example of an HIV Ag/Ab combination immunoassay that is commercially available in the US and FDA-approved for HIV diagnosis.

The performance characteristics of the ARCHITECT suggest that the assay may also be useful for distinguishing recent from late or chronic HIV infection for the purposes of estimating HIV-1 incidence. The ARCHITECT is a chemiluminescent microparticle immunoassay (CMIA) that detects HIV-1/2 antibodies in serum or plasma, as well as HIV-1 p24 antigen. The chemiluminescent reaction resulting from the detection of HIV antibody and antigen is measured as relative light units (RLU) and a signal to cutoff ratio (S/Co) is calculated based on the reactivity of the specimen relative to an internal assay calibrator. Studies have demonstrated the ability of the ARCHITECT to detect acute infection, defined as HIV-1 NAT reactive and HIV-1 antibody negative [7–9], which is attributable to the sensitive detection of p24 antigen [10]. The ARCHITECT has a broad dynamic range for detection of the analytes and an association between S/Co and duration of infection has been demonstrated [11, 12].

HIV surveillance involves the collection of information related to new and existing cases of HIV infection and provides estimates of prevalence in a given population. The duration of HIV infection, however, cannot typically be inferred from routinely collected surveillance data and, therefore, estimation of incidence, the occurrence of new infections in a population, presents distinct challenges. Laboratory assays, developed or optimized for distinguishing recent from long-term HIV infection, allow for estimation of incidence based on a cross-sectional sampling of a population [13, 14]. Multiple HIV incidence assays have been evaluated for the measurement of a given biomarker, typically HIV antibody titers or avidity, including the commercially available HIV-1 LAg-Avidity EIA (Sedia Biosciences Corp., Portland, OR) [13, 15]. Testing for recent HIV-1 infection is typically independent of diagnostic testing, incurring
additional costs, training needs, and dedicated equipment requirements. With the advent of new diagnostic technologies, there has been growing interest in evaluating select HIV diagnostic assays for determining recent infection.

In this study, we evaluated the feasibility of using the ARCHITECT S/Co to determine recent infection, using the standard assay protocol. The performance characteristics of the assay, such as the mean duration of recent infection (MDRI) and false recent rate (FRR), were estimated based on the S/Co from well-characterized subtype B HIV-1 seroconversion panels and optimal recency cutoffs were selected. The MDRI is defined as the average time that an HIV-infected person will spend in the "recent" state, as measured by a given incidence assay, while the FRR is a measure of the misclassification of long-term HIV infections as recent. HIV-1 recency status, based on the ARCHITECT S/Co values obtained through US surveillance systems, was compared to diagnostic test results from two prior prospective HIV-1 diagnostic studies.

### Materials and methods

#### Seroconversion panels and long-term specimens

For estimation of the ARCHITECT S/Co MDRI, 198 specimens from 26 antiretroviral therapy (ART)-naïve, subtype B HIV-1-infected subjects were evaluated (Table 1). Five HIV-1 seroconversion panels (n = 42 specimens) were purchased from Zeptometrix Corp. (Buffalo, NY) and three panels (n = 14) were obtained from SeraCare Life Sciences, Inc. (Milford, MA). A total of nine longitudinal seroconversion panels (n = 82 specimens) were obtained through the Seroconversion Incidence Panel Project (SIPP) in collaboration with SeraCare Life Sciences, Inc., described in detail previously [16]. All specimens were unlinked from personal identifiers and determined not to be human subjects research by the Centers for Disease Control and Prevention. Lastly, nine recent seroconverters (n = 60 specimens) were obtained from the Women’s Interagency HIV Study (WIHS). WIHS is an ongoing, prospective, multi-center cohort study aimed towards understanding disease progression in HIV-infected women (https://statepi.jhsph.edu/wihs/word press/) [17, 18]. WIHS was established in 1993 and recruited high-risk HIV-negative or HIV-infected women into ten clinical sites: Brooklyn, NY; Bronx, NY; Chicago, IL; Los Angeles, CA; San Francisco, CA; Washington, DC; Atlanta, GA; Birmingham, AL/ Jackson, MS; Chapel Hill, NC; Miami, FL. Each site obtained approval from the local Institutional Review Board (IRB) and participants provided written informed consent.

For estimation of FRR, a total of 66 plasma specimens (single time points per study participant) were obtained from a 1982–1983 study in Atlanta, GA, involving subtype B HIV-1-infected men who have sex with men (MSM) diagnosed with lymphadenopathy [19–21]. The majority of the sample collection for the study occurred at a time prior to the advent of

| Specimen Source | # Specimens | # Participants | Median days LN-FP (min-max) | Median days follow-up (min-max) |
|-----------------|-------------|----------------|-----------------------------|-------------------------------|
| Zeptometrix     | 42          | 5              | 2 (2–8)                     | 33 (13–52.5)                 |
| SeraCare        | 14          | 3              | 4 (2–13)                    | 20 (18–50.5)                 |
| SIPP            | 82          | 9              | 30 (11–77)                  | 365 (171–644)                |
| WIHS            | 60          | 9              | 177 (135–217)               | 2641 (1138.5–3329.5)         |
| TOTAL           | 198         | 26             |                             |                               |

*aInterval of time (days) between the last negative (LN) and first positive (FP) HIV antibody test.

*bTotal number of follow-up days for each HIV-1 seroconverter (days from 1* specimen collected).

[https://doi.org/10.1371/journal.pone.0242641.t001](https://doi.org/10.1371/journal.pone.0242641.t001)
effective ART. The specimens included in this study were collected >2 years after the study entry date, since diagnostic test dates were not available for this cohort. All samples included in this study were unlinked from personal identifiers. CDC reviewed the protocol for the study and determined that CDC was not engaged in human subject research.

ARCHITECT HIV Ag/Ab combo assay

The ARCHITECT HIV Ag/Ab Combo assay was performed according to the manufacturer’s instructions without modification. Plasma specimens were centrifuged for ten minutes at 8,000 rpm, transferred to polystyrene sample cups (Abbott Laboratories) in a total volume of 200μL, and then loaded onto the ARCHITECT i2000SR. The specimens were tested in singlicate due to volume limitations. The chemiluminescent signal, as measured by the instrument, is reported as a S/Co ratio of the relative light units (RLU) of the test sample to the RLU of the cutoff determined from an ARCHITECT calibrator. In addition to the kit controls, high and low external HIV-1 positive controls were included in each run. The controls were obtained from a proficiency testing panel derived from HIV-1-seropositive serum [22]. The high and low positive controls are consistent with long-term and recent infection, respectively, as measured by a previously characterized HIV incidence assay [23].

Estimation of mean duration of recent infection (MDRI)

The MDRI was estimated with a linear binomial regression of a logit link with a cubic polynomial for the probability of testing “recent” [24]. The 95% confidence interval was obtained through bootstrapping (by resampling subjects) with 10,000 bootstrap samples. Furthermore, for seroconversion panels from Zeptometrix Corp, SIPP and SeraCare Life Sciences, Inc., the subject’s testing history was used to obtain the estimated (earliest) date of detectable infection (EDDI). However, for the WIHS cohort, the seroconversion time was estimated as the middle point between the last negative and first positive test date due to lack of testing history data. Data points longer than 800 days from the last negative and the first positive were excluded from the analysis, based on the default recency time cut-off as defined by the R package “inctool” used for MDRI estimation (ref: https://cran.r-project.org/web/packages/inctools/index.html). The MDRI was estimated at ARCHITECT S/Co values of 300, 350, 400, 450, 500, 550, and 600.

Estimation of false-recent rate (FRR)

The FRR is the probability that a subject, who is infected longer than T (defined time after infection), will produce a “recent” infection result [15, 24]. In our study, samples used to calculate the false-recent rate were from people with HIV infection for greater than T, defined as 730.5 days or two years. The recency cutoffs of 300, 350, 400, 450, 500, 550 and 600 were used for estimating FRR. The FRR was estimated with a random sampling of the MSM cohort (N = 66) based on availability of sufficient sample volume (Table 2).

Comparison of recency and diagnostic test results

In this study, 681 specimens from the Screening Targeted Populations to Interrupt On-going Chains of HIV Transmission with Enhanced Partner Notification (STOP, n = 395) [25] and Los Angeles Rapid Test (LA Study, n = 286) [9, 26, 27] studies with available ARCHITECT, Multispot or Geenius, and Aptima Qualitative assay or HIV-1 viral load (VL) results were evaluated to assess the use of ARCHITECT for determining recent infection at each selected S/Co recency cutoff. Additionally, 661 specimens (n = 98, STOP; n = 563, LA Study) from persons
Data analysis

Differences between various groups of ARCHITECT S/Co values was determined using the Mann-Whitney U test. For the purposes of this study, two acute groups were defined based on the sequence of HIV test results. Acute group 1 was defined as ARCHITECT negative, Multispot/Geenius negative or indeterminate, and Aptima/VL reactive. Acute group 2 was defined as ARCHITECT reactive, Multispot/Geenius negative or indeterminate, and Aptima/VL reactive. Established infections were defined as having a reactive test result for all three tests.

The number of recent infections for the STOP and LA studies was determined based on the number of persons with ARCHITECT S/Co values below each of the evaluated recency cutoffs, with the exception of 300 and 350. These two recency cutoffs were not evaluated due to the extremely short MDRI estimates.

Results

Mean duration of recent infection and false recent rate

The ARCHITECT S/Co for 198 specimens from 26 recent HIV-1 seroconverters demonstrated a rapid increase in assay values within the first year post-seroconversion, allowing for a clear distinction to be made between recent (<6 months) and long-term (>2 years) infection (Fig 1A). The separation in S/Co values was further illustrated through the direct comparison of S/Co values at <6 months to >6 months post-seroconversion (Fig 1B). No overlap was observed in the 25th to 75th percentile of reactivity and higher mean values were noted at >6 months as compared to <6 months (P<0.0001). Furthermore, a difference in S/Co values (P<0.0001) was also observed between the recent group (<6 months post-seroconversion) compared to values for the 248 persons with long-term infection (>2 years post-seroconversion). The mean

Table 2. ARCHITECT HIV Ag/Ab combo S/Co MDRI and FRR estimates.

| Cutoff | MDRI*(95% CI) | N recent | FRR MSMb (95% CI) |
|--------|---------------|----------|------------------|
| 300    | 103 (86, 130) | 74       | 0.0 (0.0, 0.05)  |
| 350    | 145 (101, 224)| 80       | 0.0 (0.0, 0.05)  |
| 400    | 190 (120, 281)| 88       | 1.5 (0.0004, 0.08)|
| 450    | 247 (145, 356)| 94       | 4.6 (0.01, 12.7) |
| 500    | 291 (179, 406)| 102      | 7.6 (2.5, 16.8)  |
| 550    | 366 (222, 483)| 114      | 7.6 (2.5, 16.8)  |
| 600    | 445 (283, 564)| 125      | 9.1 (3.4, 18.7)  |

*N = 198 specimens (26 Subjects)

bN = 66 specimens (66 subjects)

MDRI = mean duration of recent infection (days); FRR = false recent rate (%); CI = confidence interval

https://doi.org/10.1371/journal.pone.0242641.t002
S/Co was 228.3, 726.9, and 731.0 for the <6 months, >6 months, and >2 year post-seroconversion groups, respectively.

The MDRI estimated at the ARCHITECT S/Co cutoffs of 300, 350, 400, 450, 500, 550, and 600 are summarized in Table 2. The MDRI ranged from a minimum of 103 to a maximum of 445 days, increasing with higher cutoff values. The MDRI at cutoffs 400, 450, 500, and 550 were within six months to one year, at 190, 247, 291, and 366 days, respectively. The FRR for the MSM cohort, ranged from 0.0 to 9.1% at the different S/Co cutoffs evaluated.

Comparison of HIV-1 recency and diagnostic test results

The number of HIV diagnoses from both the STOP and LA studies is summarized by category (acute group 1, acute group 2, and established) in Table 3. For both studies, the majority of diagnoses (77%) fell within the established category (64% STOP, 94% LA study). For both acute groups, the number of recent infections was highly consistent for all cutoffs evaluated. All samples from persons in acute group 1 were ARCHITECT negative, as samples from these individuals were HIV-1 NAT reactive only and determined to be from persons with acute infection based on the CDC/APHL HIV laboratory testing algorithm. A total of 132 out of 133 samples (99.2%) in acute group 2 were determined to be from persons with recent infection (131 out of 133 for the lowest cutoff of 400). The number of recent infections identified in the

Table 3. HIV diagnostic test results summary for STOP and LA study cohorts.

| Diagnostic Test Results | Number of Recent Infections |
|-------------------------|-----------------------------|
|                         | ARCHITECT | Multispot/Geenius | Aptima/VL | N (STOP) | N (LA Study) | N (Total) | 400 | 450 | 500 | 550 | 600 |
| Acute Group 1           | NEG       | NEG/IND           | +         | 19       | 7            | 26        | 26  | 26  | 26  | 26  | 26  |
| Acute Group 2           | +         | NEG/IND           | +         | 124      | 9            | 133       | 131 | 132 | 132 | 132 | 132 |
| Established             | +         | +                 | +         | 252      | 270          | 522       | 281 | 315 | 351 | 391 | 415 |
| TOTAL                   | 395       | 286               | 681       | 438      | 473          | 509       | 549 | 549 | 549 | 549 | 573 |

*Number of recent infections for each group at the evaluated ARCHITECT HIV Ag/Ab Combo signal-to-cutoff ratios
VL = viral load; + = reactive test result; NEG = nonreactive test result; IND = indeterminate test result
established group was variable, ranging from 54% to 80% of the total established infections, increasing with higher recency cutoff value.

The distribution of ARCHITECT S/Co for the acute and established groups is shown in Fig 2A. The S/Co for all specimens within acute group 1 is below the limit of detection for the ARCHITECT. The mean S/Co was 60.4 and 407.8 for specimens from acute group 2 and the established group, respectively. A difference (P < 0.0001) was noted between the S/Co values for acute group 2 and the established group. ARCHITECT S/Co values for the established groups from the STOP and LA studies were further evaluated based on VL and reported ART use (Fig 2B). Higher S/Co values (P = 0.0472) were observed in the established group with a VL > 1,000 RNA copies/mL compared to a VL < 1,000 RNA copies/mL (median S/Co of 422.7 versus 394.9, respectively). Interestingly, a higher median S/Co ratio (P = 0.0002) was observed in the ART-use group compared to the ART-naive group (median S/Co of 419.7 versus 373.8, respectively).

Discussion

Given that HIV incidence is a valuable measure for monitoring HIV trends over time in a population, there is a continued goal to develop and evaluate methods that would reduce error associated with these estimates and to expand HIV incidence testing in settings where additional laboratory testing is not feasible. In this study, we demonstrated the performance of the ARCHITECT, an HIV-1/HIV-2 antigen/antibody combination immunoassay, for determining recent infection. The data presented in this study suggest that S/Co values obtained with the ARCHITECT can serve a dual purpose, providing both HIV diagnostic test results as well as recency data that can be incorporated into population-level incidence estimates or used for other research purposes, requiring no additional testing or modifications to the assay protocol. A S/Co recency cutoff of 400 meets the recommended acceptance criteria for HIV incidence
assays for evaluation of subtype B HIV-1 incidence. Since ARCHITECT S/Co values are available through diagnostic screening, the costs associated with estimating HIV incidence would be significantly reduced, potentially expanding the capability of some laboratories to provide recency data for population-based incidence estimation.

Recently, Suligoi et al. performed an avidity modification with the ARCHITECT and demonstrated that an avidity index, which is a measure of the binding strength between antibody and antigen, is an accurate marker for discriminating recent from long-term infection [28]. In this study, we showed that the ARCHITECT S/Co values, alone, from longitudinal seroconversion panels exhibited a biomarker maturation curve (Fig 2A) similar to other well-performing or promising incidence assays [23, 29], which is suggestive of an assay’s ability to effectively distinguish recent from long-term infection. Similarly, Grebe et al. demonstrated comparable performance between the ARCHITECT S/Co using an unmodified protocol and HIV-1 LAg-Avidity EIA [12]. However, performance characteristics of the ARCHITECT for determining recency cannot be compared between the two studies given the notable differences in subtype diversity and inclusion criteria for the specimens used to estimate MDRI. The performance of the Geenius HIV-1/2 Supplemental Assay, a single-use immunochromatographic assay that detects and differentiates antibodies to HIV-1 and HIV-2, was also evaluated for determining recent infection and preliminary findings indicate that the assay may be useful for both HIV diagnosis and recency determination [24]. One caveat to this approach is that recency is determined for the Geenius assay based on band intensity; however, the raw band intensity values are not readily accessible through the Geenius reader for the standard user limiting its utility. Given that the ARCHITECT and Geenius are frequently used concurrently for diagnosis of HIV in the US, an algorithm composed of both test results may be considered for determining recent HIV infection.

ARCHITECT S/Co values are routinely collected in some US laboratories through the implementation of the HIV diagnostic testing algorithm; therefore, we were able to demonstrate the relationship between the HIV diagnostics test results and recency determination for two prospective diagnostic studies. Here, we determined recency at the individual level, though HIV recency data are predominantly used for estimation of population-level incidence. The benefits of recency determination at the individual level are yet to be fully explored; however, there may be utility in capturing the number of recent infections in a cohort for research purposes. As demonstrated with the STOP and LA cohorts, new diagnoses determined to be established infections by the diagnostic testing algorithm include both long-term infections, as well as persons within the MDRI of the recency assay, as HIV antibody has exceeded the limit of detection for diagnostic tests but antibody titers are continuing to increase or evolve. Overall, these data suggest that the ARCHITECT S/Co ratio is predictive of time since seroconversion and has the capability to reliably detect changes in biomarker levels over time.

Although the performance characteristics of the ARCHITECT presented here are promising, additional data are needed to fine-tune the MDRI and FRR estimates. A limitation of this study is the relatively small number and limited diversity of specimens available for the MDRI and FRR analyses. Available specimen volume also prohibited duplicate testing, which is preferred to singlicate testing to account for inherent variation associated with the testing platform. Additionally, accurate MDRI estimates require longitudinal HIV seroconversion panels with a minimal interval of time between last negative and first positive HIV diagnostic test, minimal time between each serial specimen collection, and maximal total follow-up time. Well-characterized seroconversion panels that meet these criteria and contain adequate specimen volume for testing on various platforms are difficult to obtain. Furthermore, not all cohorts included in this study had sufficient HIV testing history in order to apply the EDDI method for estimating seroconversion, which requires a combination of diagnostic test results.
In such cases, seroconversion was determined based on the midpoint between the last negative and first positive test date, as employed in previous studies [23, 30].

Certain population characteristics, such as ART use, may greatly impact FRR estimates. The MSM cohort evaluated in this study is unique in that the original study enrolled participants at a time prior to the availability of effective ART, so ART likely had little to no impact on the FRR estimates. Furthermore, Abbott has recently introduced the Alinity family of diagnostic testing platforms. Further investigation is needed to determine whether the ARCHITECT and Alinity platforms can be used interchangeably for determining recent HIV infection, though an initial evaluation has indicated comparable performance for detection of HIV [31]. ART-use has proven to be problematic for most HIV incidence assays and a slight, yet significant, reduction in the median S/Co in our study was associated with VLs less than 1,000 HIV RNA copies/mL for the ARCHITECT. However, sufficient data were not available to determine whether ART-induced virus suppression leads to increased FRRs. Prior studies have recommended that HIV incidence assays be used in conjunction with VL to eliminate potential false-recent results due to suppressed VLs in persons receiving ART and elite controllers [13, 32].

In summary, the data presented here suggest that the performance characteristics of the ARCHITECT HIV Ag/Ab Combo test meets the acceptance criteria for a HIV incidence assay and, for laboratories that employ the platform for HIV diagnostic testing, the utility of the assay may be expanded for additional surveillance applications.

Acknowledgments

The authors would like to thank Alexandra Tejada at the CDC for providing training and assistance with the ARCHITECT platform. The authors would also like to thank Eduard Grebe for valuable discussions on the MDRI estimation. Use of trade names is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services, the Public Health Service, the National Institutes of Health (NIH), or the CDC. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the NIH or CDC.

Data in this manuscript were collected by the Women’s Interagency HIV Study (WIHS). WIHS (Principal Investigators): UAB-MS WIHS (Mirjam-Colette Kempf and Deborah Konkle-Parker), U01-AI-103401; Atlanta WIHS (Ighovwerha Ofotokun and Gina Wingood), U01-AI-103408; Bronx WIHS (Kathryn Anastos and Anjali Sharma), U01-AI-035004; Brooklyn WIHS (Howard Minkoff and Deborah Gustafson), U01-AI-031834; Chicago WIHS (Mardge Cohen and Audrey French), U01-AI-034993; Metropolitan Washington WIHS (Seble Kassaye), U01-AI-034994; Miami WIHS (Margaret Fischl and Lisa Metsch), U01-AI-103397; UNC WIHS (Adaora Adimora), U01-AI-103390; Connie Wofsy Women’s HIV Study, Northern California (Ruth Greenblatt, Bradley Aouizerat, and Phyllis Tien), U01-AI-034989; WIHS Data Management and Analysis Center (Stephen Gange and Elizabeth Golub), U01-AI-042590; Southern California WIHS (Joel Milam), U01-HD-032632 (WIHS I–WIHS IV).

The authors would like to thank the LA Rapid testing study participants and staff, especially Apurva Uniyal, Peter Kerndt, Lashawnda Royal, and Staeci Morita.

Author Contributions

Conceptualization: Kelly A. Curtis, Philip J. Peters, William M. Switzer.

Data curation: Donna L. Rudolph, Kevin Delaney, Kathryn Anastos, Jack DeHovitz, Seble G. Kassaye, Carl V. Hanson, Audrey L. French, Elizabeth Golub, Adaora A. Adimora, Igho Ofotokun, Hector Bolivar, Mirjam-Colette Kempf.
Formal analysis: Kelly A. Curtis, Yi Pan.
Methodology: Kelly A. Curtis, Donna L. Rudolph.
Project administration: Kelly A. Curtis.
Validation: Kelly A. Curtis.
Writing – original draft: Kelly A. Curtis.
Writing – review & editing: Kelly A. Curtis, Yi Pan, Kevin Delaney, Philip J. Peters, William M. Switzer.

References
1. APHL C. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations 2014. https://doi.org/10.15620/cdc.23447
2. Masciotra S, Smith AJ, Youngpairoj AS, Sprinkle P, Miles J, Sionean C, et al. Evaluation of the CDC proposed laboratory HIV testing algorithm among men who have sex with men (MSM) from five US metropolitan statistical areas using specimens collected in 2011. J Clin Virol. 2013; 58 Suppl 1:e8–e12. https://doi.org/10.1016/j.jcv.2013.09.002 PMID: 24342483.
3. Pandori MW, Westheimer E, Gay C, Moss N, Fu J, Hightow-Weidman LB, et al. The Multispot rapid HIV-1/HIV-2 differentiation assay is comparable with the Western blot and an immunofluorescence assay at confirming HIV infection in a prospective study in three regions of the United States. J Clin Virol. 2013; 58 Suppl 1:692–6. https://doi.org/10.1016/j.jcv.2013.10.006 PMID: 24342485.
4. Fordan S, Bennett B, Lee M, Crowe S. Comparative performance of the Geenius HIV-1/HIV-2 supplemental test in Florida’s public health testing population. J Clin Virol. 2017; 91:79–83. https://doi.org/10.1016/j.jcv.2017.04.005 PMID: 28434810.
5. Nasrullah M, Wesolowski LG, Meyer WA 3rd, Owen SM, Masciotra S, Vorwald C, et al. Performance of a fourth-generation HIV screening assay and an alternative HIV diagnostic testing algorithm. AIDS. 2013; 27(5):731–7. https://doi.org/10.1097/QAD.0b013e32835bc535 PMID: 23135170.
6. Wesolowski LG, Wroblewski K, Bennett SB, Parker MM, Hagan C, Ethridge SF, et al. Nucleic acid testing by public health referral laboratories for public health laboratories using the U.S. HIV diagnostic testing algorithm. J Clin Virol. 2015; 65:6–10. https://doi.org/10.1016/j.jcv.2015.01.017 PMID: 25766979.
7. Eshleman SH, Khaki L, Laeyendecker O, Piwowar-Manning E, Johnson-Lewis L, Husnik M, et al. Detection of individuals with acute HIV-1 infection using the ARCHITECT HIV Ag/Ab Combo assay. J Acquir Immune Defic Syndr. 2009; 52(1):121–4. https://doi.org/10.1097/QAI.0b013e3181ab61e1 PMID: 19506484.
8. Pandori MW, Hackett J Jr., Louie B, Vailari A, Dowling T, Liska S, et al. Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting. J Clin Microbiol. 2009; 47(8):2639–42. https://doi.org/10.1128/JCM.00119-09 PMID: 19535523.
9. Chavez P, Wesolowski L, Patel P, Delaney K, Owen SM. Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab Combo Assay. J Clin Virol. 2011; 52 Suppl 1:S51–5. https://doi.org/10.1016/j.jcv.2011.09.010 PMID: 21983253.
10. Kwon JA, Yoon SY, Lee CK, Lim CS, Lee KN, Sung HJ, et al. Performance evaluation of three automated human immunodeficiency virus antigen-antibody combination immunoassays. J Virol Methods. 2006; 133(1):20–6. https://doi.org/10.1016/j.jviromet.2005.10.013 PMID: 16313975.
11. Ramos EM, Harb S, Dragavon J, Swenson P, Steklar JD, Coombs RW. Performance of an alternative HIV diagnostic algorithm using the ARCHITECT HIV Ag/Ab Combo assay and potential utility of sample-to-cutoff ratio to discriminate primary from established infection. J Clin Virol. 2013; 58 Suppl 1:e38–43. https://doi.org/10.1016/j.jcv.2013.08.014 PMID: 24029686.
12. Grebe E, Welte A, Hall J, Keating SM, Facente SN, Marson K, et al. Infection Staging and Incidence Surveillance Applications of High Dynamic Range Diagnostic Immuno-Assay Platforms. J Acquir Immun Defic Syndr. 2017; 76(5):547–55. Epub 2017/09/16. https://doi.org/10.1097/QAI.0000000000001537 PMID: 28914668.
13. Murphy G, Pilcher CD, Keating SM, Kassanjee R, Facente SN, Welte A, et al. Moving towards a reliable HIV incidence test - current status, resources available, future directions and challenges ahead. Epidemiology and infection. 2017; 145(S):325–41. https://doi.org/10.1017/S0950268816002910 PMID: 28004622.
estimation. AIDS. 2010; 24(18):2763–71. https://doi.org/10.1097/QAD.0b013e32833f1142 PMID: 20975514.

15. Kassanje R, Pilcher CD, Keating SM, Facente SN, McKinney E, Price MA, et al. Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository. AIDS. 2014; 28(16):2439–49. https://doi.org/10.1097/QAD.0000000000000429 PMID: 25144218.

16. Curtis KA, Ambrose KM, Kennedy MS, Owen SM. Evaluation of dried blood spots with a multiplex assay for measuring recent HIV-1 infection. PLoS One. 2014; 9(9):e107153. https://doi.org/10.1371/journal.pone.0107153 PMID: 25232736.

17. Bacon MC, von Wyl V, Alden C, Sharp G, Robison E, Hessol N, et al. The Women’s Intergender HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol. 2005; 12(9):1013–9. https://doi.org/10.1128/CDLI.12.9.1013-1019.2005 PMID: 16148165.

18. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, et al. The Women’s Intergender HIV Study. WIHS Collaborative Study Group. Epidemiology. 1998; 9(2):117–25. PMID: 9504278.

19. Fishbein DB, Kaplan JE, Spira TJ, Miller B, Schonberger LB, Pinsky PF, et al. Unexplained lymphadenopathy in homosexual men. A longitudinal study. JAMA. 1985; 254(7):930–5. PMID: 2991618.

20. Kaplan JE, Spira TJ, Fishbein DB, Pinsky PF, Schonberger LB. Lymphadenopathy syndrome in homosexual men. Evidence for continuing risk of developing the acquired immunodeficiency syndrome. JAMA. 1987; 257(3):335–7. PMID: 2948032.

21. Kaplan JE, Spira TJ, Fishbein DB, Lynn HS. Ten-year follow-up of HIV-infected homosexual men with lymphadenopathy syndrome: evidence for continuing risk of developing AIDS. J Acquir Immune Defic Syndr. 1992; 5(6):565–70. PMID: 1588492.

22. Mei JV, Kennedy M, Linley L, Hanson D, Schiffer J, Ethridge S, et al. Standardization and monitoring of laboratory performance and quality assurance by use of the less-sensitive HIV incidence assay: seven years of results. J Acquir Immune Defic Syndr. 2011; 58(5):482–8. https://doi.org/10.1097/QAI.0b013e318230dd77 PMID: 21857352.

23. Curtis KA, Hanson DL, Price KA, Owen SM. Performance characteristics of an antibody-based multiplex kit for determining recent HIV-1 infection. PLoS One. 2017; 12(5):e0176593. https://doi.org/10.1371/journal.pone.0176593 PMID: 28472089.

24. Keating SM, Kassanje R, Lebedeva M, Facente SN, MacArthur JC, Grebe E, et al. Performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay in Detecting “Recent” HIV Infection and Calculating Population Incidence. J Acquir Immune Defic Syndr. 1992; 5(6):565–70. PMID: 1588492.

25. Peters PJ, Westheimer E, Cohen S, Hightow-Weidman LB, Moss N, Tsoi B, et al. Screening Yield of HIV Antigen/Antibody Combination and Pooled HIV RNA Testing for Acute HIV Infection in a High-Prevalence Population. JAMA. 2016; 315(7):682–90. https://doi.org/10.1001/jama.2016.0286 PMID: 26881371.

26. Delaney KP, Branson BM, Uniyal A, Phillips S, Candai D, Owen SM, et al. Evaluation of the performance characteristics of 6 rapid HIV antibody tests. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2011; 52(2):257–63. https://doi.org/10.1093/cid/ciq068 PMID: 21288853.

27. Delaney KP. Evaluation of Newly Approved HIV Antigen-Antibody Tests Individually and When Used in the CDC/APHL HIV Diagnostic Algorithm. HIV Diagnostics Conference; March 22, 2016; Atlanta, GA2016.

28. Suligoi B, Regine V, Raimondo M, Rodella A, Terlenghi L, Caruso A, et al. HIV avidity index performance using a modified fourth-generation immunoassay to detect recent HIV infections. Clin Chem Lab Med. 2017. https://doi.org/10.1515/cclm-2016-1192 PMID: 28672745.

29. Duong YT, Kassanje R, Welte A, Morgan M, De A, Dobbs T, et al. Recalibration of the limiting antigen avidity EIA to determine mean duration of recent infection in divergent HIV-1 subtypes. PLoS One. 2015; 10(2):e0114947. Epub 2015/02/25. https://doi.org/10.1371/journal.pone.0114947 PMID: 25710171.

30. Curtis KA, Kennedy MS, Charurat M, Nasidi A, Delaney K, Spira TJ, et al. Development and characterization of a bead-based, multiplex assay for estimation of recent HIV type 1 infection. AIDS Res Hum Retroviruses. 2012; 28(2):188–97. Epub 2011/05/19. https://doi.org/10.1089/aid.2011.0037 PMID: 21585287.

31. Lackner KJ. Evaluation of and experiences with the Abbott alinity clinical chemistry and immunoassay systems. LMCE 2017 & KSLM 58th Annual Meeting; Seoul, Korea2017.

32. Kassanje R, Pilcher CD, Busch MP, Murphy G, Facente SN, Keating SM, et al. Viral load criteria and threshold optimization to improve HIV incidence assay characteristics. AIDS. 2016; 30(15):2361–71. Epub 2016/07/28. https://doi.org/10.1097/QAD.0000000000001209 PMID: 27454561.